Related Experiment Video

Updated: Jun 4, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Antiplatelet combinations for prevention of atherothrombotic events

Mario Bollati1, Fiorenzo Gaita, Matteo Anselmino

  • 1Department of Internal Medicine, Division of Cardiology, University of Torino, Italy.

Vascular Health and Risk Management
|February 23, 2011
PubMed

Insights

Antiplatelet therapy is crucial for preventing atherothrombotic events. This review covers its use in primary prevention and established ischemic diseases, emphasizing adherence with fixed-dose oral formulations for dual therapy.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Atherothrombotic events pose significant health risks.
  • Antiplatelet agents are vital in managing these conditions.

Purpose of the Study:

  • To review evidence on antiplatelet therapy for primary prevention.
  • To examine antiplatelet therapy in established peripheral, cerebral, and cardiac ischemic disease.
  • To highlight fixed-dose oral formulations for adherence in dual antiplatelet therapy.

Main Methods:

  • Systematic review of existing evidence.
  • Analysis of clinical trial data.
  • Focus on adherence and fixed-dose formulations.

Main Results:

  • Antiplatelet therapy effectively reduces atherothrombotic events.
  • Evidence supports use in primary prevention and established ischemic diseases.
  • Fixed-dose oral formulations improve adherence in dual therapy regimens.

Conclusions:

  • Antiplatelet therapy is a cornerstone in preventing atherothrombotic events.
  • Adherence is critical for optimal outcomes, particularly with dual therapy.
  • Fixed-dose oral formulations are valuable for patient adherence.
Keywords:
aspirinclopidogrelfixed-dose combinationsticlopidine

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...